Sulbactam and durlobactam

(Xacduro®)

Sulbactam and durlobactam

Drug updated on 9/4/2024

Dosage FormInjection (intravenous; 1 g of sulbactam for injection [1 clear single-dose vial] and 0.5 g of durlobactam for injection [2 amber single-dose vials])
Drug ClassBeta lactamase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Xacduro (sulbactam and durlobactam) is indicated for patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • SUL-DUR demonstrated in vitro effectiveness by reverting sulbactam-resistant Acinetobacter baumannii isolates, including carbapenem-resistant strains, to a susceptible state, indicating enhanced activity of sulbactam when combined with durlobactam.
  • The review did not provide comparative effectiveness data for SUL-DUR against other drugs or specify differences in effectiveness among different population types or subgroups.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Xacduro (sulbactam and durlobactam) Prescribing Information. 2023Entasis Therapeutics Ltd., an affiliate of Innoviva Specialty Therapeutics, Waltham, MA

Systematic Reviews / Meta-Analyses